Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers

Chalabi, M; Fanchi, LF; Dijkstra, KK; Van den Berg, JG; Aalbers, AG; Sikorska, K; Lopez-Yurda, M; Grootscholten, C; Beets, GL; Snaebjornsson, P; Maas, M; Mertz, M; Veninga, V; Bounova, G; Broeks, A; Beets-Tan, RG; de Wijkerslooth, TR; van Lent, AU; Marsman, HA; Nuijten, E; Kok, NF; Kuiper, M; Verbeek, WH; Kok, M; Van Leerdam, ME; Schumacher, TN; Voest, EE; Haanen, JB

Chalabi, M; Voest, EE (corresponding author), Netherlands Canc Inst, Gastrointestinal Oncol, Amsterdam, Netherlands.; Chalabi, M; Voest, EE (corresponding author), Netherlands Canc Inst, Mol Oncol & Immunol, Amsterdam, Netherlands.; Chalabi, M (corresponding author), Netherlands Canc Inst, Med Oncol, Amsterdam, Netherlands.; Voest, EE (corresponding author), Oncode Inst, Utrecht, Netherlands.

NATURE MEDICINE, 2020; 26 (4): 566

Abstract

PD-1 plus CTLA-4 blockade is highly effective in advanced-stage, mismatch repair (MMR)-deficient (dMMR) colorectal cancers, yet not in MMR-proficient ......

Full Text Link